Related references
Note: Only part of the references are listed.Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors in Patients Undergoing Elective PCI: a Network Meta-analysis
Rahul Gupta et al.
CARDIOVASCULAR DRUGS AND THERAPY (2023)
Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevationmyocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial
Anne H. Tavenier et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials
Waiel Abusnina et al.
CARDIOVASCULAR REVASCULARIZATION MEDICINE (2022)
Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials
Claudio Montalto et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections
Jawad H. Butt et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial
Masafumi Ono et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
Effect of ticagrelormonotherapy on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials including 26 143 patients
Sung-Jin Hong et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
Do We Really Need Aspirin Loading for STEMI?
Regina Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Is Aspirin Loading Before Primary Percutaneous Coronary Intervention for Patients with ST-Elevation Myocardial Infarction Necessary?
Hiroshi Asanuma et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome-A Systematic Review and Meta-analysis
Niklas Bergh et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2022)
Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ying Ma et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2022)
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis
Mengyi Sun et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients
Mehmet Koray Adali et al.
ACTA CARDIOLOGICA (2022)
Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis
Qiufen Xie et al.
BMC CARDIOVASCULAR DISORDERS (2022)
Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack
Yongjun Wang et al.
NEUROLOGY (2022)
Cardioprotective effect of extracellular vesicles derived from ticagrelor-pretreated cardiomyocyte on hyperglycemic cardiomyocytes through alleviation of oxidative and endoplasmic reticulum stress
Ceylan Verda Bitirim et al.
SCIENTIFIC REPORTS (2022)
Antiplatelet therapy after percutaneous coronary intervention
Dominick J. Angiolillo et al.
EUROINTERVENTION (2022)
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2021)
The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis
Lina Badimon et al.
CARDIOVASCULAR RESEARCH (2021)
Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial
Byung Gyu Kim et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Xiangkai Zhao et al.
FRONTIERS IN PHARMACOLOGY (2021)
Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors
Ingrid Langer et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
Francesco Condello et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Mattia Galli et al.
LANCET (2021)
Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/transient ischemic attack-Protocol for a systematic review and network meta-analysis
Gabriele Zitikyte et al.
PLOS ONE (2021)
Ticagrelor and the risk of infections during hospitalization in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention
Xing-Ji Lian et al.
ATHEROSCLEROSIS (2021)
Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction
Marie V. Hjortbak et al.
BASIC RESEARCH IN CARDIOLOGY (2021)
Infarct size following loading with Ticagrelor/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction
Muhammad Sabbah et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2020)
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial
Remo H. M. Furtado et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome
Luca Baldetti et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Ticagrelor in Post-STEMI Adverse Ventricular Remodeling There Is More Than Meets the Platelet
Gemma Vilahur et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI)
Yongwhi Park et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial
Salahaddin Ubaid et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria
Patrizio Lancellotti et al.
JAMA CARDIOLOGY (2019)
Ticagrelor Reduces Ischemia-Reperfusion Injury Through the NF-κB-Dependent Pathway in Rats
Xiaogang Liu et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2019)
Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel
Hasseri Halim et al.
PLOS ONE (2019)
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
S. Schuepke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ticagrelor in Patients with Stable Coronary Disease and Diabetes
P. Gabriel Steg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?
Joseph Allencherril et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2019)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Borja Ibanez et al.
EUROPEAN HEART JOURNAL (2018)
Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis
Giuseppe Tarantini et al.
AMERICAN HEART JOURNAL (2018)
Caffeine and incidence of dyspnea in patients treated with ticagrelor
Daniel Lindholm et al.
AMERICAN HEART JOURNAL (2018)
Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function
Jonathon P. Audia et al.
BASIC RESEARCH IN CARDIOLOGY (2018)
P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs
Gemma Vilahur et al.
CARDIOVASCULAR RESEARCH (2018)
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
William R. Hiatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine
Yochai Birnbaum et al.
CARDIOVASCULAR DRUGS AND THERAPY (2016)
Protective Effects of Ticagrelor on Myocardial Injury After Infarction
Gemma Vilahur et al.
CIRCULATION (2016)
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack
S. Claiborne Johnston et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction
Johanne Silvain et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis
Michael R. Preusch et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Infarct Size Following Treatment With Second-Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study
Jamal N. Khan et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Understanding the Adverse Effects of Ticagrelor in Practice
Christopher B. Granger et al.
JAMA CARDIOLOGY (2016)
Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction
Yumei Ye et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings
Gilad D. Birnbaum et al.
CARDIOVASCULAR DRUGS AND THERAPY (2015)
Inflammation and Immunity in Diseases of the Arterial Tree Players and Layers
Peter Libby et al.
CIRCULATION RESEARCH (2015)
Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size An Adenosine and Cyclooxygenase-2-Dependent Effect
Manjyot K. Nanhwan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
Daniel Lindholm et al.
EUROPEAN HEART JOURNAL (2014)
Adenosine-Mediated Effects of Ticagrelor Evidence and Potential Clinical Relevance
Marco Cattaneo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome
Laurent Bonello et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Ezra A. Amsterdam et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction
Gilles Montalescot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
Robert F. Storey et al.
PLATELETS (2014)
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Patrick T. O'Gara et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2013)
Differential Effect of Ticagrelor Versus Prasugrel on Coronary Blood Flow Velocity in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Exploratory Study
Dimitrios Alexopoulos et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2013)
Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition: A Post Hoc Analysis of the TRITON-TIMI 38 Trial
Owen Mogabgab et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2013)
Inflammation in atherosclerosis: a cause or a result of vascular disorders?
Ileana Manduteanu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
P2Y12 platelet inhibition in clinical practice
Peter Damman et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)
Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2011)
Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis
Philippe Gabriel Steg et al.
CIRCULATION (2010)
Caffeine and Adenosine
Joaquim A. Ribeiro et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
Christopher P. Cannon et al.
LANCET (2010)
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model
Kai Wang et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Ticagrelor: The First Reversibly Binding Oral P2Y(12) Receptor Antagonist
Steen Husted et al.
CARDIOVASCULAR THERAPEUTICS (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2008)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Mechanisms of disease: Myocardial reperfusion injury
Derek M. Yellon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin
Yochai Birnbaum et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2007)
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2
S Atar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Optimal windows of statin use for immediate infarct limitation -: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase
S Sanada et al.
CIRCULATION (2004)
Left ventricular remodeling after myocardial infarction - Pathophysiology and therapy
MGS Sutton et al.
CIRCULATION (2000)
Adenosine prevents activation of transcription factor NF-κB and enhances activator protein-1 binding activity in ischemic rat heart
CF Li et al.
SURGERY (2000)